The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance

Launched by COPENHAGEN UNIVERSITY HOSPITAL, HVIDOVRE · Jan 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a specific type of medication called anti-IL-17 might help improve breathing problems in people with asthma. The researchers want to see if this treatment can reduce airway hyperreactivity, which means how sensitive the airways are to triggers that can make it hard to breathe. They will look at how people's breathing changes before and after starting the treatment by using tests to measure airflow in the lungs.

To participate in this study, you need to be an adult who is planning to start anti-IL-17 treatment for skin or joint conditions. However, there are some health conditions that may prevent you from joining, such as being pregnant, having serious heart issues recently, or certain lung function problems. If you qualify and decide to join, you will undergo tests to measure your breathing at the beginning and after starting the treatment. This study could help determine if anti-IL-17 is effective for asthma patients, which could lead to new treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients planning to start treatment with anti-IL-17 antibodies
• Exclusion Criteria:
• • Current pregnancy
• • FEV1 \< 1.5L or less than 60% of predicted value expected.
• • Previous anaphylactic shock or severe allergic reaction to medicine
• • Uncontrolled hypertension
• • Myocardial infarction or stroke within the last 3 months
• • Known aortic aneurysm
• • Recent eye surgery or risk of elevated intracranial pressure
• • Treatment with systemic corticosteroids within 6 weeks